A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or
Refractory B-cell Acute Lymphoblastic Leukemia
This phase I trial evaluates the side effects and best dose of BAFFR-CAR T cells in treating
patients with B-cell Acute Lymphoblastic Leukemia that has come back (recurrent) or does not
respond to treatment (refractory). T cells are infection fighting blood cells that can kill
cancer cells. The T cells given in this study will come from the patient and will have a new
gene put in them that makes them able to recognize BAFFR, a protein on the surface of cancer
cells. These BAFFR-specific T cells may help the body's immune system identify and kill
BAFFR+ cancer cells.
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.